Company Encyclopedia
View More
name
JUNSHI BIO
01877.HK
Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in the therapeutic areas of malignant tumors, neurological, autoimmune, chronic metabolic, nervous system, and infectious diseases in the People's Republic of China. The company was founded in 2012 and is headquartered in Shanghai, People's Republic of China.
1.377 T
01877.HKMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
BiotechnologyIndustry
Industry Ranking17/52
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-15.33%E
    • Profit Margin-38.25%E
    • Gross Margin84.45%A
  • Growth ScoreB
    • Revenue YoY37.50%A
    • Net Profit YoY47.87%B
    • Total Assets YoY6.16%B
    • Net Assets YoY-1.14%D
  • Cash ScoreC
    • Cash Flow Margin-261.41%D
    • OCF YoY37.50%A
  • Operating ScoreD
    • Turnover0.22D
  • Debt ScoreC
    • Gearing Ratio46.14%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Junshi Biosciences Announces Primary Endpoints Met in JS001sc's Phase 3 Study for the 1ST-line Treatment of NSQ-NSCLC

    The phase 3 study of toripalimab's subcutaneous injection (JS001sc) has met primary endpoints ...

    GlobeNewswire·
    HK
    01877
    -1.67%
    SH
    688180
    +0.70%
    GlobeNewswire·
    HK
    01877
    -1.67%
    SH
    688180
    +0.70%

    Junshi Biosciences Reports Phase III Success for Subcutaneous Toripalimab in NSCLC

    Shanghai Junshi Biosciences Co. Ltd. announced the success of its phase III clinical study for JS001SC, a subcutaneous formulation of toripalimab, in treating recurrent or metastatic non-squamous non-small cell lung cancer. The study met its primary endpoints, showing non-inferior drug exposure compared to existing toripalimab injections, with similar efficacy and safety. The company plans to present detailed data at an international conference and submit a new drug application for JS001SC.

    Reuters·
    SH
    688180
    +0.70%
    HK
    01877
    -1.67%
    Reuters·
    SH
    688180
    +0.70%
    HK
    01877
    -1.67%

    J.P. Morgan Remains a Sell on Shanghai Junshi Biosciences Co., Ltd. Class H (1877)

    According to TipRanks, Huang is a 5-star analyst with an average return of 36.9% and a 67.57% success rate. Huang covers the Healthcare sector, focusing on stocks such as Innovent Biologics, Wuxi Biologics (Cayman), and Hangzhou Tigermed Consulting Co., Ltd. Class H. The word on The Street in general, suggests a Hold analyst consensus rating for Shanghai Junshi Biosciences Co., Ltd. Class H with a HK$30.56 average price target.

    Tip Ranks·
    SH
    688180
    +0.70%
    HK
    01877
    -1.67%
    Tip Ranks·
    SH
    688180
    +0.70%
    HK
    01877
    -1.67%

    Zhitong Hong Kong Stock Short Position Statistics | October 31

    As of October 24, the three stocks with the highest short interest ratios in the Hong Kong stock market are ZTE Corporation (15.82%), CHINA VANKE (15.47%), and COSCO SHIP HOLD (15.42%). The stocks with the largest increases in short interest ratios are Junshi Biosciences-B, Sanhua Intelligent Controls, and Giant Biogene, which increased by 2.41%, 2.04%, and 1.06%, respectively. The stocks with the largest decreases in short interest ratios are JUNSHI BIO, MING YUAN CLOUD, and SD GOLD, which decreased by 0.95%, 0.94%, and 0.93%, respectively

    Zhitong·
    SH
    688180
    +0.70%
    HK
    01877
    -1.67%
    SZ
    000002
    -0.40%
    Zhitong·
    SH
    688180
    +0.70%
    HK
    01877
    -1.67%
    SZ
    000002
    -0.40%

    Hong Kong stocks in the innovative drug concept sector continue to strengthen, with RemeGen rising over 8%

    Hong Kong stocks related to innovative pharmaceuticals continue to strengthen, with RemeGen rising over 8%, INNOVENT BIO rising over 7%, and FOSUN PHARMA, JUNSHI BIO, and JOINN rising over 5%

    Zhitong·
    SH
    600196
    +0.63%
    HK
    02196
    +1.03%
    SH
    688180
    +0.70%
    Zhitong·
    SH
    600196
    +0.63%
    HK
    02196
    +1.03%
    SH
    688180
    +0.70%
    © 2025 Longbridge｜Disclaimer